ArticleScientific reports2026
Development, psychometric validation, and correlates of the 15-item quality of life in epilepsy scale (QOLIE-15).
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medication adherence in epilepsy: Validation of the short medication adherence scale (SMAS-7) and mediation analysis of quality-of-life pathways.Exploratory research in clinical and social pharmacy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health-related quality of life (HRQoL) is a central outcome in epilepsy care, but existing tools are either lengthy, too brief, or lack sensitivity to epilepsy-specific concerns. This study developed and validated the 15-item Quality of Life in Epilepsy Scale (QOLIE-15) and examined sociodemographic, socioeconomic, clinical, and psychosocial determinants of HRQoL. A cross-sectional study was conducted among adult patients with epilepsy recruited from community pharmacies and a primary healthcare center. Participants completed the QOL assessment alongside established measures of medication adherence, adverse events, cognition, anxiety, and stigma. The dataset was randomly split for exploratory and confirmatory factor analysis (EFA and CFA). Reliability, convergent, concurrent, and criterion validity were assessed. Measurement invariance was tested across gender, seizure characteristics, and seizure control. Multivariable linear regression identified independent predictors of QOLIE-15 scores. The study included 649 patients. EFA supported a stable 5-factor structure, with sampling adequacy confirmed by KMO = 0.875 and Bartlett’s test (P < 0.001). CFA demonstrated excellent fit (CFI = 0.978, TLI = 0.972, RMSEA = 0.041, SRMR = 0.034). Internal consistency was high (α = 0.906, ω = 0.929). The QOLIE-15 correlated strongly with QOLIE-31 (r = 0.875) and showed excellent criterion validity, with a cut-off of 44.5 yielding sensitivity of 88.8% and specificity of 82.0%. Measurement invariance was established across key subgroups. In multivariable analysis, lower QOL was independently associated with uncontrolled seizures (B = − 1.53), adverse drug effects (B = − 0.10), stigma (B = − 0.38), cognitive complaints (B = − 0.28), anxiety (B = − 0.52), and higher household crowding (B = − 0.77). The QOLIE-15 is a valid, reliable, and practical instrument capturing epilepsy-specific HRQoL. It balances brevity with multidimensionality, and its invariance and robust psychometric properties support application in clinical practice and research. Independent determinants highlight the importance of addressing seizure control, treatment tolerability, stigma, cognition, and anxiety in epilepsy care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.